These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15744814)

  • 1. Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.
    Moon SH; Shin KH; Suh JS; Yang WI; Noh JK; Hahn SB
    Yonsei Med J; 2005 Feb; 46(1):119-24. PubMed ID: 15744814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
    Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children].
    Muñoz Villa A; Ocete G; Aymerich ML; Maldonado S; Otheo E; Calvo M; Amaya J
    Med Clin (Barc); 1996 Jun; 107(5):161-4. PubMed ID: 8758673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma.
    Shin KH; Moon SH; Suh JS; Yang WI
    Clin Orthop Relat Res; 2000 Jul; (376):200-8. PubMed ID: 10906876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
    Bernthal NM; Federman N; Eilber FR; Nelson SD; Eckardt JJ; Eilber FC; Tap WD
    Cancer; 2012 Dec; 118(23):5888-93. PubMed ID: 22648705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
    Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
    Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of postradiation osteosarcoma does not correlate with chemotherapy response.
    Lewis VO; Raymond K; Mirza AN; Lin P; Yasko AW
    Clin Orthop Relat Res; 2006 Sep; 450():60-6. PubMed ID: 16906104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
    Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
    J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
    Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
    Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis.
    Wang W; Wang ZC; Shen H; Xie JJ; Lu H
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1383-90. PubMed ID: 24867518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
    Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
    Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
    Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
    J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.